Latest Breaking News On - Patients with heart - Page 1 : comparemela.com

Safia Chatur, MD: Sacubitril/Valsartan Offers Benefit in HFrEF Across New KDIGO Risk Classes

Safia Chatur, MD, discusses the results of a PARADIGM-HF analysis at ACC.24 examining the effects of ARNI use across the updated 2024 KDIGO Risk Classifications.

United statesSafia chaturColl cardiolWork groupAmerican college of cardiologyAmerican collegeAnnual scientific sessionsDisease improving global outcomesMassachusetts general hospitalHazard ratioConfidence intervalValsartan acrossRenal impairmentPatients with heartImproving global outcomesPractice guideline

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSteve dabkowskiSilviu itescuPaul hughesMesoblast limited nasdaqMesoblast the companyAustralian securities exchangeDrug administrationDrug designation programCorporate communications investorsJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

United States Food & Drug Administration (FDA) Grants

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory.

United statesSteve dabkowskiSilviu itescuPaul hughesDrug administrationCorporate communications investorsAustralian securities exchangeMesoblast the companyDrug designation programMesoblast limited nasdaqJournal of the american college cardiologyUnited states foodOrphan drug designationRare pediatric disease designationChief executive silviu itescuCardiovascular surgery open

United States Food & Drug Administration (FDA) Grants

FDA GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR® (REXLEMESTROCEL-L) IN CHILDREN WITH CONGENITAL HEART DISEASE.

United statesSilviu itescuSteve dabkowskiPaul hughesMesoblast limited nasdaqDrug administrationJournal of the american college cardiologyCorporate communications investorsAustralian securities exchangeRevascor increases size of left heart chamberMesoblast the companyLeft heart chamberImproves surgical outcomesHypoplastic left heart syndromeResults publishedCardiovascular surgery

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaul hughesSteve dabkowskiSilviu itescuMesoblast limited nasdaqCorporate communications investorsJournal of the american college cardiologyDrug administrationAustralian securities exchangeMesoblast the companyRevascor increases size of left heart chamberLeft heart chamberImproves surgical outcomesHypoplastic left heart syndromeResults publishedCardiovascular surgery